

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)




PCT/EP 00 / 05841



INVESTOR IN PEOPLE

EP00/5841


**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ4
10/018704

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 6 June 2000

THIS PAGE BLANK (USPTO)



For Official use

29 JUN 1999

29 JUN 1999

30JUN99 E458430-1 D02029
P01/7700 0.00 - 9915204.3

Your Reference: MJWD/B45187

9915204.3

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-483 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

- ② Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The Patent Office Request for grant of a Patent
Form 1/77 Patents Act 1977

① Title of invention

1 Please give the title of the invention **VACCINE**

② Applicant's details

☐ First or only applicant

2a If you are applying as a corporate body please give:
Corporate Name **SmithKline Beecham Biologicals s.a.**

Country (and State of incorporation, if appropriate) **Belgium**

2b If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2c In all cases, please give the following details:

Address: **rue de l'Institut 89, B-1330 Rixensart**

UK postcode (if applicable)

Country **Belgium**

ADP number **5800974002**
(if known)

6570956001

2d, 2e and 2f: If there are further applicants please provide details on a separate sheet of paper



Second applicant (if any)

2d

If you are applying as a corporate body please give:
Corporate Name

Country (and State of
Incorporation, if appropriate)

2e

If you are applying as an individual or one of a partnership please give in full:

Surname:

Forenames:

2f

In all cases, please give the following details:

Address:

UK postcode

(if applicable)

Country

ADP number

(if known)

3

An address for
service in the United Kingdom
must be supplied

Please mark correct box.

3

Address for service details

3a

Have you appointed an agent to deal with your application?

Yes ☒

No ☐ go to 3b



please give details below

Agent's name MARCUS J W DALTON

Agent's address
SmithKline Beecham
Corporate Intellectual Property
New Horizons Court
Great West Road
Brentford, Middlesex

Postcode

TW8 9EP

Agent's ADP
number

4122313006

3b: If you have appointed an agent,
all correspondence concerning
your application will be sent to the
agent's United Kingdom address.

3b

If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name

Address

Postcode

number

ADP number

(if known)

Daytime telephone

(if available)

④ Reference number

4. Agent's or
applicant's reference MJWD/B45187
number (if applicable)

⑤ Claiming an earlier application date

5. Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes ☐

No ☒ go to 6



please give details below

☐ number of earlier
application or patent
number

☐ filing date (day month year)

☐ and the Section of the Patents Act 1977 under which you are
claiming:

15(4) (Divisional) ☐ 8(3) ☐ 12(6) ☐ 37(4) ☐

⑥ Declaration of priority

6. If you are declaring priority from previous application(s), please give:

Country of Filing	Priority application number (if known)	Filing Date (day, month, year)

Please mark correct box

Please mark correct box

⑥ If you are declaring priority from a
PCT Application please enter 'PCT'
as the country and enter the country
code (for example, GB) as part of
the application number

*Please give the date in all number
format, for example, 31/05/90 for
31 May 1990*

7

- any applicant is not an inventor
- there is an inventor who is not
- an applicant, or
- any applicant is a corporate body.

- 8 Please supply duplicates of claim(s), abstract, description and drawings).

Please mark correct box(es)

- 9 You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.


Please sign here **ā**

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7. Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes ☐ No ☒ 

A Statement of Inventorship on Patents form 7/77 will need to be filed (see Rule 15).).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application

Continuation sheets for this Patents Form 1/77

Claim(s) 1

Description 14

Abstract

Drawing(s) 4 0 1 7

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant


Patents Form 9/77 - Preliminary Examination Report

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed


 MARCUS J W DALTON
 Chartered Patent Attorney
 Attorney for the Applicant

Date: 29/06/99

(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either;

☐ The Comptroller or

☒ The Comptroller

The Patent Office

The Patent Office

Cardiff Road

Harmsworth House

Newport

13-15 Bouverie Street

Gwent

London

NP9 1RH

EC4Y 8DP

VACCINES

The present invention relates to a novel vaccine formulations and their use in medicine, particularly in the prevention of malaria infections. In particular the present invention is concerned with a CpG oligonucleotide and a malarial antigen.

Malaria, is one of the world's major health problems with 2 to 4 million people dying from the disease each year. One of the most acute forms of the disease is caused by the protozoan parasite, Plasmodium falciparum which is responsible for most of the mortality attributable to Malaria.

The life cycle of P. falciparum is complex, requiring two hosts, man and mosquito for completion. The infection of man is initiated by the inoculation of sporozoites in the saliva of an infected mosquito. The sporozoites migrate to the liver and there infect hepatocytes where they differentiate, via the exoerythrocytic intracellular stage, into the merozoite stage which infects red blood cells (RBC) to initiate cyclical replication in the asexual blood stage. The cycle is completed by the differentiation of a number of merozoites in the RBC into sexual stage gametocytes which are ingested by the mosquito, where they develop through a series of stages in the midgut to produce sporozoites which migrate to the salivary gland.

The sporozoite stage of P. falciparum has been identified as a potential target of a malaria vaccine. The major surface protein of the sporozoite is known as circumsporozoite protein (CS Protein). This protein from strain 7G8 has been cloned, expressed and sequenced (Dame et al Science 225 (1984) p593). The protein from strain 7G8 is characterised by having a central immunodominant repeat region comprising a tetrapeptide Asn-Ala-Asn-Pro repeated 37 times but interspersed with four minor repeats Asn-Val-Asp-Pro. In other strains the number of major and minor repeats vary as well as their relative position. This central portion is flanked by an N and C terminal portion composed of non-repetitive amino acid sequences designated as the repeatless portion of the CS protein.

It has been shown that irradiated sporozoites can provide significant protection against experimental human malaria (Am. J. Trop. Med. Hyg. 24: 297-402, 1975). However, production difficulties makes the use of irradiated sporozoite impractical from the point of view of producing a vaccine.

5

Several groups have proposed subunit vaccines based on the circumsporozoite protein. Two of these vaccines have undergone clinical testing; one is a synthetic peptide, the other is a recombinant protein (Ballou et al Lancet: i 1277 (1987) and Herrington et al Nature 328:257 (1987).

10

These vaccines were successful in stimulating an anti-sporozoite response. Nonetheless, the magnitude of the response was disappointing, with some vaccinees not making a response at all. Furthermore, the absence of "boosting" of antibody levels on subsequent injections and results of in vitro lymphocyte proliferation assays suggested that T-cells of most of these volunteers did not recognise the immuno-dominant repeat. Nonetheless, one vaccinee in each study did not develop parasitemia.

15

The present invention provides a new, improved malaria vaccines which not only produces a humoral response, but also a cellular immune response. Preferably the antigen induces the production of neutralising antibodies against the immunodominant repeat. Most preferably, the antigen should also elicit effector T cell mediated immune responses of the CD4⁺ and CD8⁺ cytotoxic T lymphocyte (CTL) type and of the delayed type hypersensitivity type and also, preferably be able to induce T helper (TH) memory cells.

20

25

International patent application No. WO 93 / 10152 (SmithKline Beecham Biologicals s.a) provides a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandem repeats of the

30

immunodominant region, and the Surface antigen from Hepatitis B virus (HBsAg). Preferably the hybrid protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal portion of the CS

protein. The CS protein may be devoid of the last 12 amino-acids from the C terminal.

5 In particular there is provided a protein which comprises a portion of the CS protein of *P. falciparum* substantially as corresponding to amino acids 210-398 of *P. falciparum* 7G8 fused in frame via a linear linker to the N-terminal of HBsAg. The linker may comprise a portion of preS2 from HBsAg.

10 A particularly preferred embodiment is the hybrid protein designated RTS. This hybrid consists of:

- 15 • A methionine-residue, encoded by nucleotides 1059 to 1061, derived from the *Sacchromyes cerevisiae* TDH3 gene sequence. (Musti A.M. et al Gene 1983 25 133-143.
- Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
- 20 • A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 210 to 398 of the circumsporozoite protein (CSP) of *Plasmodium falciparum* strain 7G8 (Dame et al supra).
- An amino acid (Arg) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- 25 • Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (9).
- 30 • A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype).

In an alternative embodiment there is provided a hybrid protein designated RTS* which was generated using the CSP gene sequence from *P. falciparum* NF54 (Mol. Biochem Parasitol. 35 : 185-190, 1989) and comprises substantially all of the region 207 to 395 of the CS protein from *P falciparum* NF54.

5

In particular RTS* comprises:

- A Methionine, encoded by nucleotides 1059 to 1061, derived from the TDH3 gene sequence.
- Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
- A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 207 to 395 of the circumsporozoite protein (CSP) of *Plasmodium falciparum* strain NF54 (Mol.Biochem.Parasitol, 35:185-190, 1989).
- An amino acid (Gly) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (Nature 280:815-819, 1979).
- A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype) (Nature 280:815-819, 1979)

25

30 International patent application no. Wo 90/01496 describe an antigen known as Trap from *P. falciparum*. An apparent homologue of Trap is described in Wo92/11868 and relates to an antigen called SSP2 from *P. yeolii*.

International patent application WO 98/ 05355 describes, inter alia, a malaria vaccine based on a combination of Trap and RTS,S.

- 5 Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides ("CpG") and are known (WO 96/02555, EP 468520). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were
- 10 shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in immunostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain
- 15 sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.

- It is currently believed that this evolutionary difference allows the vertebrate immune system to detect the presence of bacterial DNA (as occurring during an
- 20 infection) leading consequently to the stimulation of the immune system. The immunostimulatory sequence as defined by Krieg is:

Purine Purine CG pyrimidine pyrimidine and where the CG motif is not methylated.
~~In certain combinations of the six nucleotides a palindromic sequence is present.~~

- 25 Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon γ and have
-
- ~~cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977).~~
- 30 Although other unmethylated CpG containing sequences not having this consensus sequence have now been shown to be immunomodulatory.
-

The present invention provides an improved vaccine formulation comprising a CpG oligonucleotide and an malaria antigen. In particular, RTS,S or RTS,S* or Trap or immunologically equivalent derivatives thereof.

- 5 Vaccine preparation is generally described in Vaccine Design - The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.
- 10 The preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides. The oligonucleotides of the present invention are typically deoxynucleotides. In a preferred embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other internucleotide bonds are within the scope
- 15 of the invention including oligonucleotides with mixed internucleotide linkages.

Preferred oligonucleotides have the following sequences: The sequences preferably contain all phosphorodithioate modified internucleotide linkages.

- | | | |
|----|---|---------|
| | TCC ATG ACG TTC CTG ACG TT | (WD001) |
| 20 | ACC GAT AAC GTT GCC GGT GACG | (WD002) |
| | TCT CCC AGC GTG CGC CAT | (WD003) |
| | ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG | (WD007) |

-
- The CpG oligonucleotides utilised in the present invention may be synthesized by
- 25 any method known in the art (eg EP 468520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US5,666,153, US5,278,302 and WO95/26204.
-

- 30 The amount of protein in each vaccine does is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is
-

employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 µg of protein, preferably 2-100 µg, most preferably 5-50 µg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an
5 initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

Suitably the CpG will be present in the range 10 µg per dose to 100 µg, preferably 25-75 µg, such as 50 µg per dose.

10

Suitably the vaccine used in the present invention may comprise a carrier such as an aluminium salt, eg aluminium hydroxide (Al(OH)₃), aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.

15

If an aluminium salt (preferably aluminium hydroxide) is used as a carrier it is generally present in the range of 50 to 100 µg, preferably 100 to 500 µg per dose.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, eg squalene and
20 an emulsifier such as (polysorbitan monoleate) Tween 80, in an aqueous carrier such as phosphate buffered saline.

If desired the vaccine used in the present invention may comprise an additional
~~adjuvant, preferably a saponin adjuvant such as QS21 as described for example in~~
25 WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464.

Accordingly vaccine formulations of the present invention may additionally
~~comprise other pharmaceutical excipients or immunostimulants. In a preferred~~
30 embodiment the vaccine formulation additionally comprises an aluminium salt,

preferably aluminium hydroxide. In a further embodiment a saponin adjuvant may also be included such as QS21 (Aquila).

5 The present invention will now be described with reference to the following examples:

IMMUNOGENICITY STUDIES USING RTS,S FORMULATED WITH CPG OR CPG/ALUM

10 Evaluation of CpG and CpG/alum in mice

Experiment outline

An immunogenicity study was conducted to evaluate the ability of CpG to serve as an adjuvant for cytotoxic T lymphocyte (CTL) induction. Groups of mice were immunized with RTS,S formulated with CpG oligonucleotide alone or in
15 combination with aluminum hydroxide. After two immunizations spleen cells were examined for the presence of HbsAg-specific effector cells.

Table 1: Groups of mice

Group	antigen	adjuvant
1	RTS,S	CpG/alum
2	RTS,S	CpG

20

Formulation

Component batches used:

COMPONENT	BRAND	BATCH NUMBER	CONCENTRATION (MG/ML)	BUFFER
RTSS		24R51	0.664	P/N 6.8
Al(OH) ₃	Superfos	97A0027	10.380	H ₂ O
CpG (WD001)	Eurogen etech	324255R1	5	H ₂ O

Formulation process:

Formulations were prepared 3 days before each injection. All incubations were
5 carried out at room temperature with agitation.

CpG/alum group 1 (500µl/dose)

RTSS (8.7µg) and gp120 (8.7µg) were adsorbed on 100µg of Al(OH)₃ or AlPO₄ for
1 hour. The formulation was buffered with a 10-fold concentrated PO₄/NaCl pH
10 6.8 solution before addition of 100µg of CpG (WD001). After 15 min, 50 µg/ml of
thiomersal was added as preservative.

CpG group 2 (500µl/dose)

RTSS (8.7µg) and Gp120(8.7µg) were diluted in PBS pH 6.8 before addition of
15 100µg of CpG (WD001). After 5 min, 50 µg/ml of thiomersal was added as
preservative.

Immunological methods

Nine Balb/C mice per group received into the hind footpads 100 µl vaccine twice at
20 a two-week-interval. Two weeks later spleen cells were harvested and used to
determine the induction of HBsAg-specific CTL.

For CTL analysis cells were cultured for 7 days in 6-well plates in the presence of
10 µg per ml of synthetic peptide pCMI003 corresponding to an HBsAg CTL

epitope (Schirmbeck et al., 1995). At the end of the culture period cells were assessed in duplicate for HBsAg-specific cytolytic activity in standard [⁵¹Cr]-release assays using control and S-transfected P815 cells. Minimum and maximum release were determined with target cells without effector cells and by the addition of 3 %
 5 (v/v) Triton X-100, respectively. Results are expressed as % [⁵¹Cr]-release (cpm of exp. culture - cpm of spont. release / cpm of max. release - cpm of spont. release).

Results

Spleen cells from both groups of mice exhibited HBsAg-specific effector cell
 10 function in ⁵¹Cr release assays (Figure 1). Untransfected P815 target cells were lysed to a much lesser degree than similar target cells expressing the HBV s gene. Lysis of the target cells diminished with decreasing effector to target cell ratios.

Conclusions

15 Immunization with RTS,S in combination with CpG or CpG/alum induces HBsAg-specific CTL in mice.

EVALUATION OF CPG AND CPG/ALUM IN RHESUS MONKEYS

20 *Experiment outline*

An immunogenicity study was conducted to evaluate the adjuvant effect of CpG in non-human primates. Groups of five monkeys were immunized twice with RTS,S in combination with CpG or CpG/alum. After the second immunization the immune
 response of the animals was assessed. Antibodies to HBsAg and lymphoproliferative
 25 as well as cytokine responses were evaluated.

Table 2. Groups of monkeys

Group	antigen	adjuvant
1	RTS,S	CpG/alum
2	RTS,S	CpG

Formulation*Component batches used:*

COMPONENT	BRAND	BATCH NUMBER	CONCENTRATION (MG/ML)	Buffer
RTS,S		ERTS1X058	1.372	P/N 6.8
Al(OH) ₃	Superfos	96A0089	10.380	H ₂ O
CpG		WD001	5	H ₂ O

5

Formulation process:

Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.

CpG/alum group 1 (500µl/dose)

10

RTSS (50µg) was adsorbed on 500µg of Al(OH)₃ for 1 hour. The formulation was buffered with a 10-fold concentrated PO₄/NaCl pH 6.8 solution before addition of 500µg of CpG (WD001). After 15 min, 50 µg/ml of thiomersal was added as preservative.

15 H₂O + Al(OH)₃ + RTSS-1H-10xPN-15m-CpG-15m-Thio

CpG group 2 (500µl/dose)

RTSS (50µg) was diluted in PO₄/NaCl buffer pH 6.8 before addition of 500µg of CpG WD001. After 15 min, 50 µg/ml of thiomersal was added as preservative.

20

H₂O + RTSS + 10xPN-15m-CpG-15m-Thio

Immunological methods

Five rhesus monkeys (*Macaca mulatta*) per group were immunized twice intramuscularly with 500 μ l of vaccine at a four-week-interval. Sera and peripheral blood mononuclear cells (PBMC) were taken at several occasions.

5

HBsAg-specific antibodies in monkey sera were determined in a radio immuno assay (RIA, Abbott) according to the manufacturer's instructions.

10 Lymphoproliferation was assessed by using density gradient-purified PBMC from immunized rhesus monkeys. Cells were seeded in quadruplicates at 1×10^5 in 100 μ l RPMI/5 % FCS per well in round bottom 96 well plates. Then another 100 μ l of medium alone or containing soluble RTS,S (10 μ g/ml) were added and parallel cultures were incubated for 48 hrs. Thereafter, 100 μ l culture supernatant were replaced by fresh medium containing 1 μ Ci [3 H]-thymidine. After 16 hrs cells were
15 harvested onto filter plates and incorporated radioactivity was determined in a β -counter. Results are expressed in cpm and in stimulation indices (SI, = cpm antigen-containing cultures/cpm medium alone cultures), SI greater than 3 are considered as a positive response.

20 Flat bottom 96 well plates were prepared by coating an IFN- γ -specific capture antibody in 50 μ l PBS for 4 hrs at 37 °C. The plates were washed three times and PBMC were seeded similar to lymphoproliferation assays. After 48 hrs of culture the plates were washed thrice with PBS/0.05 % Tween 20 and 50 μ l of biotinylated secondary IFN- γ -specific antibody diluted in PBS/Tween/1 % FCS were added for
25 2 hrs. The plates were washed again and a gold-conjugated α -biotin antibody was incubated for 1 hr. After additional washings the ELIspots were visualized by using a silver enhancing kit (50 μ l per well). The reaction was stopped after approx. 30 min by adding deionized water. Cytokine-secreting cells were enumerated by
microscopic examination.

30

Results

Analysis of HBsAg-specific antibodies in sera of the monkeys revealed that all animals in the two groups had developed specific immune responses (Figure 2).

Some responses were detectable already after one immunization. Interestingly, these
5 responses were boosted by the second immunization only in group 1, while titers in group 2 remained more or less constant.

Induction of specific lymphoproliferation by immunization with RTS,S in combination with CpG or CpG/alum was evaluated before immunization and 6 days
10 post secondary immunization. All 10 animals did not exhibit any specific lymphoproliferation ($SI > 3$) at the study start (data not shown). In contrast, all animals in group 1 possessed strong lymphoproliferative responses 6 days post boost immunization (Figure 3). All animals from group 2 did, however, remain negative in this analysis.

15 The presence of RTS,S-specific IFN- γ -secreting cells was investigated in all monkeys before immunization and 6 days after the second dose. IFN- γ -secreting cells could not be evaluated from pre-immunization samples due to technical difficulties. However, such cells were detectable after secondary immunization
20 (Figure 4). All animals in group 1 exhibited a positive response, while only one animal in group 2 was positive.

Conclusions

Immunization with RTS,S in combination with CpG induces immune responses in
25 non-human primates. After two immunizations CpG alone induces low level HBsAg-specific antibodies, while CpG combined with alum induces high titer antibodies as well as vigorous lymphoproliferative and IFN- γ responses.

Figure legends

Figure 1: CTL activity of spleen cells from immunized mice. Effector cell activity was assessed by examining ^{51}Cr release of P815 cells (open circles) or s-transfected P815 cells (closed circles).

5

Figure 2: HBsAg-specific antibody responses in immunized rhesus monkeys. Specific antibodies were evaluated using a commercially available RIA. Individual values from multiple time points for each animal are shown in the table, and group averages are shown in the table and as a graphic.

10

Figure 3: RTS,S-specific lymphoproliferation in immunized rhesus monkeys 6 days post second immunization. PBMC were stimulated with RTS,S antigen and lymphoproliferative responses were measured by ^3H -thymidine incorporation. Results are expressed in cpm and as SI.

15

Figure 4: RTS,S-specific IFN- γ -secreting cells from immunized rhesus monkeys. IFN- γ -secreting cells were visualized by the ELISpot method. Cytokine-secreting cells resulting in a colored spot were enumerated by microscopic examination and results are expressed semi-quantitatively (- = 0-5, + = 5-15, ++ = 15-35, +++ = 35-50, ++++ = >50).

20

References


Schirmbeck, R., Boehm, W., Melber, K., Reimann, J. (1995). Processing of exogenous heat-aggregated (denatured) and particulate (native) Hepatitis B surface antigen for class I-restricted epitope presentation. J. Immunol. 155:4676-4684.

25

Claims:

1. A vaccine formulation comprising a malaria antigen and an immunostimulatory CpG oligonucleotide.
2. A vaccine as claimed in claim 1 wherein the antigen is selected from the group, RTS, RTS*, TRAP or immunologically equivalent derivatives.
3. A vaccine as claimed in claim 1 or 2 wherein the vaccine comprises TRAP or immunologically equivalent derivative and one of RTS or RTS*.
4. A vaccine formulation as claimed herein additionally comprising an aluminium salt or a saponin adjuvant.
5. A vaccine as claimed herein wherein the oligonucleotide comprises two CpG dinucleotides.
6. A vaccine as claimed herein wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
7. A vaccine as claimed herein wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.
8. A vaccine as claimed herein wherein the oligonucleotide is selected from the group:
 - WD000 1: TCC ATG ACG TTC CTG ACG TT
 - WD000 2: TCT CCC AGC GTG CGC CAT
 - WD000 3: ACC GAT AAC GTT GCC GGT GAC G
 - WD000 7: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG
9. A method for the prevention or amelioration of plasmodium infection a patient, comprising administering an effective amount of a vaccine of claim 1 to 8 to patient.
10. A vaccine as claimed herein for use as a medicament.
11. A method of producing a vaccine as claimed in any of claim 1 to 8 comprising ~~adminixing a malarial antigen and a CpG immunostimulatory oligonucleotide.~~

THIS PAGE BLANK (USPTO)


Figure 1:

THIS PAGE BLANK (USPTO)

Figure 2:



Titer anti-HBs (m UI/ml-RIA)

	d-12	average	14 d post I	average	7 d post II	average	28 d post II	average
Group 1	N5V	<1	115		921		1352	
	I055	<1	76		6424		1112	
	R441	<1	222	193	369	1907	431	888
	BXJ	8	121		862		546	
	CPJ	<1	430		960		997	
Group 2	NJ5	<1	<1		17		11	
	X006	4	4		51		37	
	I041	<1	11	29	42	71	5	35
	R361	<1	2		68		62	
	BBE	3	100		175		61	



THIS PAGE BLANK (USPTO)

Figure 3:



THIS PAGE BLANK (USPTO)

Figure 4:

Group 1					
	N5V	I055	R441	BXJ	CPJ
RTS,S	+	++	++	++	++
Unstimulated cells	-	-	-	-	-
					5/5

Group 2					
	NJ5	X006	I041	R361	BBE
RTS,S	-	+	+++	+	-
Unstimulated cells	-	+	+	+	-
					1/5

THIS PAGE BLANK (USPTO)